D&D Pharmatech to Present Zabopegdutide Phase 2 Trial Results at SOLAR Shark Tank

Neuraly, the U.S. subsidiary of D&D Pharmatech, has been invited to present at the Shark Tank session of the 'SOLAR Conference 2026,' an academic event focused on MASH (Metabolic dysfunction-associated steatohepatitis). Neuraly will directly explain the Phase 2 clinical trial results of Zabopegdutide in front of executives from major pharmaceutical companies. This move comes after the company released tissue biopsy data last month at the European Association for the Study of the Liver (EASL 2026) and signals the start of full-scale discussions on global partnering.

According to industry sources on June 23, the SOLAR Conference 2026, held from June 25 to 27 in San Juan, Puerto Rico, is a global academic event that shares the latest research and clinical development strategies in MASH and related diagnostic fields. Dr. Mazen Noureddin and Dr. Naim Alkhouri, both world-renowned authorities in MASH and liver diseases, will serve as co-chairs of the academic program. Experts and key executives from the global pharmaceutical and biotech industries will attend to discuss clinical data and new drug development trends.

The 'Shark Tank' session in which Neuraly will participate differs from typical academic presentations. Presenting companies will deliver their clinical data and development strategies before a panel composed of leading industry and academic opinion leaders, as well as executives from global pharmaceutical companies. These companies will engage in in-depth discussions and real-time Q&A sessions, exchanging diverse perspectives on clinical differentiation, development strategy, and commercial potential.

The panel for this session will include leading figures such as Dr. Mazen Noureddin and Dr. Naim Alkhouri, both experts in the MASH field; Dr. David Soergel, Chief Medical Officer (CMO) of Madrigal Pharmaceuticals, the developer of the first MASH treatment, Resmetirom; Nikhil Burgess, Clinical Lead for Liver Diseases at GSK; and Rami Younes, Global Head of Clinical Development at Boehringer Ingelheim, among other key representatives from leading global pharmaceutical companies.

Adam Bell, Executive Vice President and Head of Translational Medicine and Regulatory Affairs at Neuraly, will speak at the event. He will share the recently released, competitive Phase 2 tissue biopsy results for Zabopegdutide and discuss their clinical significance and future development strategies with the panel.

The company believes that this event presents a significant opportunity to showcase the clinical competitiveness and development potential of Zabopegdutide directly to leading global pharmaceutical companies and key experts in the MASH field. In addition, D&D Pharmatech aims to further expand ongoing global partnering discussions and explore various collaboration opportunities through this event.

Seulgi Lee, CEO of D&D Pharmatech, stated, "It is meaningful to present the outstanding Phase 2 results of Zabopegdutide before experts and senior executives who are leading the paradigm of the global market. Through our participation in SOLAR 2026, we will do our best to promote the clinical value and differentiated competitiveness of Zabopegdutide in the global market and to expand future development and global partnering opportunities."

This content was produced with the assistance of AI translation services.